287 related articles for article (PubMed ID: 15180893)
1. B cell depletion in autoimmune disease.
Gorman C; Leandro M; Isenberg D
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
[TBL] [Abstract][Full Text] [Related]
2. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
3. B-cell depletion and repopulation in autoimmune diseases.
Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
[TBL] [Abstract][Full Text] [Related]
4. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
5. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
Kazkaz H; Isenberg D
Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
[TBL] [Abstract][Full Text] [Related]
6. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.
Chambers SA; Isenberg D
Lupus; 2005; 14(3):210-4. PubMed ID: 15807198
[TBL] [Abstract][Full Text] [Related]
7. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
8. Rituximab.
Doan T; Massarotti E
Drugs Today (Barc); 2005 Dec; 41(12):785-97. PubMed ID: 16474854
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
10. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
Pescovitz MD
Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.
Silverman GJ; Weisman S
Arthritis Rheum; 2003 Jun; 48(6):1484-92. PubMed ID: 12794814
[No Abstract] [Full Text] [Related]
12. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.
Silverman GJ
Front Biosci; 2007 Jan; 12():2194-206. PubMed ID: 17127456
[TBL] [Abstract][Full Text] [Related]
13. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
Hainsworth JD
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
16. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Sfikakis PP; Boletis JN; Tsokos GC
Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
[TBL] [Abstract][Full Text] [Related]
17. [CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka Y
Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
[No Abstract] [Full Text] [Related]
18. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
Gorman C; Leandro M; Isenberg D
Lupus; 2004; 13(5):312-6. PubMed ID: 15230284
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
20. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
